Geopolitical tensions show need for more made-in-Canada medicines, pharma stakeholders tell House Health Committee
Witnesses told MPs that global conflicts and new U.S. policies should motivate the federal government to improve its regulatory processes to ensure that companies want to produce their pharmaceuticals in Canada.
Improving access to made-in-Canada medicines is not only good for the public’s health, but also for national security, says witnesses during a recent meeting of the House Health Committee as it began a study on the idea of “pharmaceutical sovereignty.”
Get Today's Headlines Newsletter
Wake up to the day's top political and policy headlines. Weekday Mornings.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
